Panelists discuss how managing overactive bladder in older adults requires a holistic approach that integrates treatment of comorbidities, emerging therapeutic options, and quality-of-life ...

A panelist discusses how significant unmet needs in NMIBC treatment persist around BCG supply shortages, optimal treatment sequencing, biomarker development for patient selection, and reducing ...

Data for newer therapies have shown that more than 50% of patients with BCG-unresponsive NMIBC experience a complete response after just 3 months of treatment. What are your thoughts on these findings ...

"My biggest hope for people reading this review is to understand that there are some golden opportunities for research," says Laura Bukavina, MD, MPH, MSc. Isali: I think our review mainly highlighted ...

"The notion that the urine is sterile should be hopefully abolished by now, especially in this group where we know that these individuals do have a lot of bacteria growing in their bladders," says ...

PSMA PET imaging can lead to significant stage migration in mHSPC, affecting treatment decisions and patient outcomes. 40.3% of patients experienced stage changes with PSMA PET, including shifts from ...

The RELIEF ureteral stent is the first FDA-cleared stent for vesicoureteral reflux prevention in the US. The stent's design minimizes bladder spasms and reflux, improving patient comfort compared to ...

"I think integrating microbiome surveillance into clinical trials can bridge the gap between research and also therapeutic applications," says Ilaha Isali, MD, MSc. The abstract suggests that ...

ImmunityBio aims to expand Anktiva's approval for BCG-unresponsive NMIBC with papillary tumors, potentially reducing radical cystectomy rates. The QUILT-3.032 trial demonstrated promising disease-free ...

“What creates job satisfaction are 3 principles: mastery, autonomy, and a sense of purpose,” says Mark T. Edney, MD. In this video, Mark T. Edney, MD, highlights the 3 key principles that improve job ...

“The patients I find that have the most pronounced benefit are the patients with the very large prostates, or the patients who are catheter dependent with concern for neurogenic or myogenic bladder ...

How has the introduction of targeted gene therapy changed the way you approach managing BCG-unresponsive NMIBC? What are the broader implications of using gene therapy to treat BCG-unresponsive NMIBC, ...